Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $22.50, for a total value of $22,500.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.72, for a total transaction of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.

Enliven Therapeutics Price Performance

Shares of Enliven Therapeutics stock opened at $24.70 on Wednesday. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The firm has a market capitalization of $1.16 billion, a P/E ratio of -11.28 and a beta of 1.05. The company’s 50 day moving average price is $17.67 and its two-hundred day moving average price is $14.89.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics in the third quarter worth about $157,000. China Universal Asset Management Co. Ltd. purchased a new position in Enliven Therapeutics in the fourth quarter worth $66,000. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 9.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. AJOVista LLC bought a new stake in Enliven Therapeutics during the fourth quarter worth about $28,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after buying an additional 2,208 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.